Interestingly, the positive antineoplastic synergistic effects of asciminib and ponatinib in patients with T315I-mutated CP-CML have been demonstrated in CML cell lines (25); however, the potential influence of ponatinib pretreatment is unclear. This evidence concerns the gene CP and chronic myelogenous leukemia, BCR-ABL1 positive.